Organovo is a company that specialises in bioprinting – the laboratory engineering of tissue. Bioengineering is also the focus of several other universities and research instates around the world, but unlikesome of thesecompanies working with printed live tissue with a focus on sustainability issues by producing edible, 3D printed meat, Organovo’s focus is on the medical sector — specifically on producing live human tissue.
Watch Andras Forgacs, a co-founder of Organovo explain the process and philosophy behind bioprinting – in a very clear manner – in the short video below.
The manufacturing machinery supporting Organovo’s process is the NovoGen MMX Bioprinter™. And while printing transplantable organs is still some years off in terms of research and testing, Organovo’s bioprinter can now be used for groundbreaking research of another kind – the study of the effects of (new) pharmaceuticals using functional 3D printed human tissue.
This alone would be a valid reason for introducing and highlighting the company here on 3DPI, but the key factor here is that the NovoGen MMX is the only proven-to-work, commercially available bioprinter in the world — a truly momentous achievement that points to further barriers being broken down and taking one step closer to a breakthrough for organ generation when donations are not forthcoming.
About Organovo:
Organovo is focused on delivering breakthrough three-dimensional biology capabilities to create tissue on demand for research and surgical applications. As the first company with a three-dimensional tissue technology that works across tissue types, we are meeting the promise of regenerative medicine to fill unmet medical needs.
